hVIVO plc (OPORF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

hVIVO plc (OPORF) Healthcare & Pipeline Overview

hVIVO plc is a London-based pharmaceutical service and contract research organization specializing in human challenge clinical trials for vaccines and antivirals. Serving big pharma, biotech, and government, the company leverages its unique disease models and the 'Disease in Motion' platform to generate critical data for infectious disease progression, positioning it as a key partner in drug development.

What Is the Investment Thesis for OPORF?

hVIVO plc presents a unique investment profile centered on its specialized human challenge clinical trial capabilities and its 'Disease in Motion' data platform. The company's expertise in controlled human infection models for conditions like RSV, flu, and COVID-19 positions it as a critical partner for pharmaceutical and governmental entities seeking efficient and precise vaccine and antiviral development data. With a market capitalization of $75.5M, hVIVO operates with a reported profit margin of -12.5% and a gross margin of -6.1%, indicating a growth-focused stage where investments in research models and platform development are ongoing. The company's beta of 1.69 suggests higher volatility relative to the broader market. Key growth catalysts include the expansion of its human challenge model portfolio, particularly the development of new models for emerging infectious diseases, and the commercialization of its 'Disease in Motion' platform to a wider array of clients, including big tech and wearables. The consistent demand for contract research services in the biotechnology sector further supports its operational pipeline. Risks include the inherent challenges of operating with negative margins, regulatory hurdles associated with human challenge trials, and competition in the broader CRO market, though its specialization provides a distinct competitive edge. The 2.42% dividend yield provides some income, but the primary value drivers are tied to its specialized services and data monetization.

Based on FMP financials and quantitative analysis

OPORF Key Highlights

Market Capitalization of $75.5M reflects the company's current valuation within the biotechnology services sector.

• Profit Margin of -12.5% indicates the company is currently operating at a loss, potentially due to ongoing investments in research models and platform development.
• Gross Margin of -6.1% suggests that the cost of services provided exceeds the revenue generated from those services, highlighting operational efficiency challenges or strategic pricing.
• A Beta of 1.69 indicates that hVIVO plc's stock price tends to be more volatile than the overall market, suggesting higher risk and potential for larger price swings.
• A Dividend Yield of 2.42% provides shareholders with a return, despite the company's current negative profitability, which can be attractive to certain investor profiles.

Who Are OPORF's Competitors?

OPORF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OPORF's Key Strengths?

Highly specialized expertise in human challenge clinical trials for infectious diseases.

• Proprietary 'Disease in Motion' platform with unique multi-modal biomarker data.
• Diverse client base including big pharma, biotech, and government organizations.
• Comprehensive service offering from preclinical to early clinical research and consultancy.
• Agile development of new models, such as the COVID-19 human challenge study model.

What Are OPORF's Weaknesses?

Currently operating with negative profit and gross margins (-12.5% and -6.1% respectively).

• Reliance on a highly specialized and regulated clinical trial methodology.
• Market capitalization of $75.5M suggests a relatively small scale compared to larger CROs.
• Higher stock volatility indicated by a Beta of 1.69.
• Disclosure status on OTC market is 'Unknown', potentially limiting investor information.

What Could Drive OPORF Stock Higher?

OPORF catalyst: Successful development and launch of new human challenge study models, such as the COVID-19 model, attracting new contracts and expanding service offerings.

• Announcement of new significant contracts or partnerships with major pharmaceutical companies or government agencies for vaccine and antiviral testing.
• Commercialization or licensing agreements for the 'Disease in Motion' platform, generating new revenue streams from tech or pharma sectors.
• Continued growth in demand for specialized contract research organization (CRO) services within the European biotechnology sector.
• Positive clinical outcomes or data releases from ongoing human challenge trials, enhancing the company's reputation and attracting further research opportunities.

What Are the Key Risks for OPORF?

Negative return on equity (-14.7%) — the business is not currently generating profit on shareholder capital.

• Continued operation with negative profit and gross margins, impacting long-term financial sustainability and requiring ongoing capital infusions.
• Regulatory scrutiny and ethical considerations inherent in human challenge clinical trials, which could lead to delays or restrictions on operations.
• Intense competition from larger, more diversified contract research organizations (CROs) that may offer broader service portfolios or greater financial resources.
• Volatility in the stock price, as indicated by a Beta of 1.69, which could expose investors to significant fluctuations.
• Dependence on the successful development and adoption of new disease models and the 'Disease in Motion' platform for future revenue growth.

What Are the Growth Opportunities for OPORF?

• Expansion of human challenge models: The development and validation of new human challenge study models, such as the ongoing work for COVID-19 and potential future pathogens, represent a significant growth avenue. As global health threats evolve, the demand for rapid and effective vaccine and antiviral testing increases. hVIVO's ability to create and deploy these specialized models for conditions like RSV, flu, and potentially others, positions it to capture a larger share of the infectious disease drug development market, attracting new clients seeking expedited and scientifically rigorous data.
• Leveraging the Disease in Motion platform: The 'Disease in Motion' platform, with its rich datasets of clinical, immunological, virological, and digital biomarkers, offers substantial potential for monetization beyond traditional CRO services. By providing insights into infectious disease progression, this platform can be licensed or utilized by big technology companies for health monitoring, wearable device manufacturers for advanced diagnostics, and other pharma/biotech firms for drug discovery and personalized medicine, creating new, high-margin revenue streams.
• Increased demand for specialized CRO services: The global pharmaceutical industry continues to rely heavily on contract research organizations to manage the complexities and costs of drug development. hVIVO's comprehensive suite of preclinical and early clinical research services, coupled with its unique human challenge capabilities, positions it to benefit from this ongoing outsourcing trend. As European pharmaceutical clients seek specialized expertise in infectious disease research, hVIVO can expand its client base and secure more extensive, long-term contracts.
• Strategic partnerships with government and public health organizations: hVIVO's existing relationships with government and public health organizations provide a foundation for securing significant contracts related to national and international health initiatives. Collaborations on pandemic preparedness, vaccine stockpiling, and rapid response to outbreaks can lead to stable, large-scale projects. These partnerships not only provide substantial revenue but also enhance hVIVO's reputation as a critical player in global health security.
• Geographic expansion and market penetration: While hVIVO primarily serves European pharmaceutical clients, the specialized nature of its human challenge models and the global need for infectious disease research present opportunities for geographic expansion. Targeting key pharmaceutical hubs in North America or Asia could significantly broaden its client base. By strategically marketing its unique capabilities, hVIVO can penetrate new markets and establish itself as a global leader in human challenge trials and infectious disease data analytics.

What Are OPORF's Competitive Advantages?

• Specialized expertise in human challenge clinical trials, a niche and highly regulated area of drug development.
• Proprietary portfolio of human challenge study models for a range of infectious diseases, including RSV, flu, and COVID-19.
• The 'Disease in Motion' platform, offering unique and comprehensive datasets from clinical, immunological, virological, and digital biomarkers.
• Established relationships with big pharma, biotech, government, and public health organizations, indicating trust and a track record.
• Integrated service offering, combining specialized trials with broader CRO and consultancy services, creating a holistic solution for clients.

What Does OPORF Do?

hVIVO plc, headquartered in London, United Kingdom, operates as a specialized pharmaceutical service and contract research company within the biotechnology sector. The company's core expertise lies in conducting human challenge clinical trials, a unique methodology for testing vaccines and antivirals by safely exposing volunteers to infectious agents in a controlled environment. This approach provides efficient and high-quality data on disease progression and drug efficacy, serving a diverse client base that includes major pharmaceutical companies, biotechnology firms, government agencies, and public health organizations across Europe. Originally known as Open Orphan Plc, the company rebranded to hVIVO plc in October 2022, reflecting its focused evolution in the human challenge trial space. Its extensive portfolio of human challenge study models covers a range of conditions such as Respiratory Syncytial Virus (RSV), influenza, human rhinovirus, asthma, malaria, cough, and Chronic Obstructive Pulmonary Disease (COPD). Notably, hVIVO is also actively developing a COVID-19 human challenge study model, addressing ongoing global health needs. Beyond its specialized trials, hVIVO is developing the 'Disease in Motion' platform, a proprietary database of infectious disease progression data. This platform integrates unique datasets encompassing clinical, immunological, virological, and digital (wearable) biomarkers, offering significant potential applications for various end-users, including big technology companies, wearable device manufacturers, and other pharmaceutical and biotech entities. Furthermore, the company offers a comprehensive suite of preclinical and early clinical research services, sales and marketing support, biometry, data management, and statistical analysis to its European pharmaceutical clients. hVIVO also provides drug development consultancy, including Chemistry, Manufacturing, and Controls (CMC), pharmacokinetics (PK), and medical writing services, solidifying its role as an integrated partner in the drug development lifecycle.

What Products and Services Does OPORF Offer?

• Conduct human challenge clinical trials for vaccines and antivirals.
• Develop and maintain a portfolio of human challenge study models for various conditions like RSV, flu, and COVID-19.
• Provide preclinical and early clinical research services to pharmaceutical clients.
• Offer biometry, data management, and statistical analysis services.
• Develop and manage the 'Disease in Motion' platform, a database of infectious disease progression data.
• Provide drug development consultancy, including CMC, PK, and medical writing services.
• Serve big pharma, biotech, government, and public health organizations.

How Does OPORF Make Money?

• Generates revenue through fees for conducting human challenge clinical trials for clients.
• Earns income from providing comprehensive contract research services, including preclinical and early clinical research.
• Monetizes data and insights from its 'Disease in Motion' platform through potential licensing or partnerships with tech and pharma companies.
• Provides consultancy and support services (e.g., biometry, medical writing) on a fee-for-service basis to European pharmaceutical clients.

What Industry Does OPORF Operate In?

hVIVO plc operates within the dynamic and specialized biotechnology industry, specifically as a contract research organization (CRO) with a niche focus on human challenge clinical trials. The broader CRO market is characterized by increasing outsourcing trends from pharmaceutical and biotech companies seeking to reduce R&D costs and accelerate drug development timelines. hVIVO's unique position stems from its ability to conduct controlled human infection studies, which offer a highly efficient and ethical pathway for testing vaccines and antivirals compared to traditional field trials. This specialization places it in a less crowded segment of the CRO market, where expertise in infectious disease models like RSV, flu, and emerging pathogens is highly valued. The industry is driven by continuous innovation in drug discovery, global health challenges, and the need for robust clinical data, all of which hVIVO addresses through its service offerings and its 'Disease in Motion' data platform. The competitive landscape includes larger, more diversified CROs, but hVIVO's specific human challenge model portfolio provides a distinct competitive advantage.

Who Are OPORF's Key Customers?

• Big pharmaceutical companies seeking to test vaccines and antivirals.
• Biotechnology firms developing new infectious disease treatments.
• Government agencies and public health organizations involved in disease prevention and control.
• Big technology companies and wearable device manufacturers interested in disease progression data.
• European pharmaceutical clients requiring preclinical, early clinical, and consultancy services.

Company Profile

hVIVO plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Yamin Mohammed Khan. OPORF has traded publicly since 2020.

hVIVO plc Financial Trajectory

hVIVO plc (OPORF) reported $22.6M in revenue for Q4 2025, a decline of 11.3% compared to the prior quarter. The company recorded a net loss of $5.9M, with diluted EPS of $-0.01. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, OPORF averaged $0.00 in diluted EPS.

How hVIVO plc Is Valued

hVIVO plc carries a market capitalization of $75.5M, placing it in the micro-cap category. Relative to its peer group, OPORF's quantitative score of 49/100 is below the peer average of 76/100.

Return on equity for hVIVO plc stands at -14.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.3%, the inverse of the P/E and a quick read on earnings relative to price.

hVIVO plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.84 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project hVIVO plc revenue of about $50.2M for fiscal 2026, with EPS near $-0.01. The estimate reflects 8 contributing analysts.

OPORF Financials

OPORF Latest News

No recent news available for OPORF.

OPORF Analyst Consensus

OPORF MoonshotScore

OPORF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources